{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:34Z","timestamp":1790614894355,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Inovio Pharmaceuticals"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI078675"],"award-info":[{"award-number":["U19 AI078675"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI092843"],"award-info":[{"award-number":["R01 AI092843"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI109646"],"award-info":[{"award-number":["U19 AI109646"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.03.086","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T22:55:08Z","timestamp":1429138508000},"page":"4313-4320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model"],"prefix":"10.1016","volume":"33","author":[{"given":"Daniel O.","family":"Villarreal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Svoronos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan C.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon J.","family":"Shedlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2015.03.086_bib0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines\u2014what's the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.086_bib0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.086_bib0185","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"issue":"6071","key":"10.1016\/j.vaccine.2015.03.086_bib0190","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.1215418","article-title":"The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses","volume":"335","author":"Bonilla","year":"2012","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.086_bib0195","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-13-2729","article-title":"Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity","volume":"74","author":"Villarreal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coi.2014.03.004","article-title":"Interleukin-33: a switch-hitting cytokine","volume":"28C","author":"Villarreal","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.086_bib0205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2015.03.086_bib0210","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1128\/JVI.63.10.4311-4316.1989","article-title":"Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection","volume":"63","author":"Klavinskis","year":"1989","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.086_bib0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0042-6822(90)90336-P","article-title":"Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope","volume":"178","author":"Klavinskis","year":"1990","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.086_bib0220","first-page":"2650","article-title":"Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past","volume":"4","author":"Zhou","year":"2012","journal-title":"Present Future Viruses"},{"issue":"39","key":"10.1016\/j.vaccine.2015.03.086_bib0225","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1016\/j.vaccine.2010.12.064","article-title":"A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge","volume":"29","author":"Shedlock","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.086_bib0230","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/JVI.69.4.2684-2688.1995","article-title":"DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection","volume":"69","author":"Yokoyama","year":"1995","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.086_bib0235","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.20061937","article-title":"Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection","volume":"204","author":"Shin","year":"2007","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.086_bib0240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.086_bib0245","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.immuni.2013.05.009","article-title":"Effector-like CD8(+) T cells in the memory population mediate potent protective immunity","volume":"38","author":"Olson","year":"2013","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.086_bib0250","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.4049\/jimmunol.175.7.4677","article-title":"Recall proliferation potential of memory CD8+ T cells and antiviral protection","volume":"175","author":"Bachmann","year":"2005","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.086_bib0255","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.086_bib0260","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.086_bib0265","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8 T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.086_bib0270","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/eji.201141629","article-title":"IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells","volume":"41","author":"Yang","year":"2011","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.03.086_bib0275","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.4049\/jimmunol.1200137","article-title":"Contribution of pulmonary KLRG1(high) and KLRG1(low) CD8 T cells to effector and memory responses during influenza virus infection","volume":"189","author":"Ye","year":"2012","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.086_bib0280","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni969","article-title":"Similarities and differences in CD4+ and CD8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.086_bib0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation directs memory precursor and short-lived effector CD8 T cells fates via the graded expression of T-bet transcription factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"issue":"26","key":"10.1016\/j.vaccine.2015.03.086_bib0290","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1073\/pnas.261570598","article-title":"T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells","volume":"98","author":"Lighvani","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"10.1016\/j.vaccine.2015.03.086_bib0295","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1016\/j.vaccine.2011.05.076","article-title":"Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine","volume":"29","author":"Yan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0300","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/cgt.2013.52","article-title":"Hydrodynamic immunization leads to poor CD8 T cell expansion, low frequency of memory CTLs and ineffective antiviral protection","volume":"20","author":"Obeng-Adjei","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0305","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/mt.2013.61","article-title":"Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola","volume":"21","author":"Shedlock","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0310","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distrubution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0315","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1128\/JVI.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosnato","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.03.086_bib0320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4049\/jimmunol.1200259","article-title":"Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion","volume":"189","author":"Luzina","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.03.086_bib0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2796.2010.02316.x","article-title":"Interleukin-33: a novel mediator with a role in distinct disease pathologies","volume":"269","author":"Kuroswska-stolarska","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.03.086_bib0335","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.086_bib0340","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.4049\/jimmunol.1201540","article-title":"Vaccine-induced effector memory CD8 T cell responses predict therapeutic efficacy against tumors","volume":"189","author":"Van Duikeren","year":"2012","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T23:03:59Z","timestamp":1598915039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":34,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15004168"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}